Haleon Unveils China Innovation Center in Shanghai to Drive Consumer Health Innovation

ShanghaiOctober 11, 2023/PR Newswire/ --One of the world's leading consumer health companies — Haleon (Haleon's first innovation center in China officially opened in Shanghai on October 10.

Haleon China Innovation Center Aims to Build a Localization-Oriented Innovation Platform in the Chinese Market

Chief Research and Development Officer of HaleonFranck Riot"At the opening ceremony of the Innovation Center, it was stated: 'China is one of the most important markets for Haleon globally. The establishment of the China Innovation Center will help us better serve Chinese consumers, realize Haleon's vision in China, and become a growth engine for our global business. In the future, we will strongly support the operation of Haleon’s China Innovation Center and continue to invest in the research, development, and innovation capabilities within the Chinese market.'"

Haleon Innovation Center, located on the 25th floor of Qiantan International Plaza, features innovation workspaces, an innovation exhibition area, sample preparation and tasting facilities, office areas for cross-functional teams, consumer research interview rooms, a shopper science lab, and facilities connected to the Suzhou laboratory, among others. It is not only a physical space but also a platform that encourages innovation, where over 100 talented individuals from various functional departments such as R&D, marketing, sales, quality, CBIA, digital and technology, strategic planning, and market access gather to exchange ideas, iterate on innovative practices, and collectively shape the future of Haleon and the consumer healthcare industry.

Haleon's competitive advantage comes from the combination of trusted science accumulated over many years and a profound understanding of human health. By leveraging its internal capabilities and advanced data and analytics from external partners, Haleon gains deep insights into consumers' mindsets, experiences, preferences, and behaviors to develop a thorough understanding of human health behaviors. Globally, Haleon has a dedicated R&D team of more than 1,400 scientists and consistently invests 3% of its annual revenue in R&D. Since becoming an independent consumer health company in 2022, Haleon has accelerated its R&D pace. In 2022, Haleon launched 9 new products in China; in 2023, the number of new product launches in China reached 13.

The inauguration of Haleon China Innovation Center marks another significant step in the development of Haleon's core operational capabilities in China. In the future, Haleon will continue to adhere to its principle of "putting people first and enhancing daily health," gaining deeper insights into the evolving needs and market trends of Chinese consumers. It aims to develop more innovative products with competitive advantages to meet unfulfilled consumer demands and provide breakthrough, superior solutions through trusted science and cutting-edge digital technologies. This commitment will further drive innovation and development in China’s health consumer sector.

About Haleon

Haleon (LSE/NYSE: HLN) aims to become a global leader in the consumer health sector, upholding the company mission of "Human-centric, enhancing daily health." Haleon's product portfolio covers five major categories: oral health, pain management, respiratory health, digestive health, and nutritional health. By combining trusted science with an understanding of human health, Haleon has built iconic brands, including Caltrate, Centrum, Sensodyne, Panadol, Voltaren, Contac, Bactroban, Flixonase, and Polident.

For more information, please refer towww.haleon.com